Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Down 20.5% in September

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,740,000 shares, a drop of 20.5% from the September 15th total of 2,190,000 shares. Based on an average daily volume of 10,250,000 shares, the short-interest ratio is currently 0.2 days.

Applied DNA Sciences Trading Down 3.7 %

NASDAQ APDN traded down $0.01 during trading on Monday, reaching $0.30. The company’s stock had a trading volume of 854,033 shares, compared to its average volume of 3,688,915. The stock has a market capitalization of $298,947.50, a PE ratio of -0.02 and a beta of 0.34. The business has a 50-day moving average price of $1.10 and a 200-day moving average price of $2.11. Applied DNA Sciences has a 1-year low of $0.29 and a 1-year high of $22.80.

Applied DNA Sciences (NASDAQ:APDN) last issued its quarterly earnings data on Thursday, August 8th. The technology company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $1.11. Applied DNA Sciences had a negative net margin of 214.42% and a negative return on equity of 138.41%. The business had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.95 million. During the same period in the previous year, the company earned ($4.80) earnings per share. As a group, analysts expect that Applied DNA Sciences will post -1.8 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Applied DNA Sciences to a “sell” rating in a report on Tuesday, September 17th.

Institutional Trading of Applied DNA Sciences

A hedge fund recently raised its stake in Applied DNA Sciences stock. AMH Equity Ltd lifted its position in Applied DNA Sciences, Inc. (NASDAQ:APDN) by 46.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 540,385 shares of the technology company’s stock after buying an additional 170,385 shares during the quarter. AMH Equity Ltd owned about 63.57% of Applied DNA Sciences worth $222,000 as of its most recent filing with the Securities and Exchange Commission. 22.22% of the stock is currently owned by institutional investors.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.